Aminopyrimidine kinase inhibitors

US9629840B2 · kind B2 · utility

Assignee

• Jasco Pharmaceuticals, LLC · US

Inventors

• Carmen M. Baldino · Woburn, US
• Justin L. Caserta · Billerica, US
• Chee-Seng Lee · Somerville, US
• Stephane Dumas · Cambridge, US
• Yvonne L. Flanders · Medford, US

Key dates

• Filing date: Dec 19, 2014
• Grant date: Apr 25, 2017
• Expiry date: Dec 19, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/65586
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.